-
Product Insights
Leukodystrophies - Drugs In Development, 2024
Empower your strategies with our Leukodystrophies – Drugs In Development, 2024 report and make more profitable business decisions. Leukodystrophies, a collection of rare genetic disorders impacting the central nervous system (CNS), specifically the brain and spinal cord, cause damage to the CNS's white matter. This damage hampers or obstructs signals between nerve cells, resulting in varied symptoms such as movement difficulties, vision and hearing impairment, and cognitive challenges. Due to the multitude of leukodystrophy types with differing symptoms, diagnosis poses a...
-
Product Insights
Essential Tremor - Drugs In Development, 2024
Empower your strategies with our Essential Tremor – Drugs In Development, 2024 report and make more profitable business decisions. Essential tremor, formerly known as benign essential tremor or familial tremor, stands as one of the most prevalent movement disorders. Defined by a tremor in hands and arms during action, it may also impact the head, voice, or lower limbs without additional neurological signs. Onset can occur at any age, with adolescence and middle age (between 40 and 50) being common. The...
-
Product Insights
Cerebral Palsy - Drugs In Development, 2024
Empower your strategies with our Cerebral Palsy – Drugs In Development, 2024 report and make more profitable business decisions. Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walking on the toes, speech problems (dysarthria), hearing or vision problems,...
-
Product Insights
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drugs In Development, 2024
Empower your strategies with our Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic inflammatory demyelinating polyneuropathy (CIDP), also called as chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal; orthostatic dizziness; and tingling and numbness of hands...
-
Product Insights
Generalized Seizures - Drugs In Development, 2024
Empower your strategies with our Generalized Seizures – Drugs In Development, 2024 report and make more profitable business decisions. Generalized seizures, are a type of seizure that impairs consciousness and distorts the electrical activity of the whole or a larger portion of the brain. It occurs when the abnormal electrical activity causing a seizure begins in both halves (hemispheres) of the brain at the same time. Generalized seizures occur in various seizure syndromes, including myoclonic epilepsy, familial neonatal convulsions, childhood absence...
-
Product Insights
Relapsing Multiple Sclerosis (RMS) - Drugs In Development, 2024
Empower your strategies with our Relapsing Multiple Sclerosis (RMS) – Drugs In Development, 2024 report and make more profitable business decisions. Multiple sclerosis (MS) is the most common disabling neurological disease of young adults with symptom onset generally occurring between the ages of 20 to 40 years. In MS, the immune system cells that normally protect us from viruses, bacteria, and unhealthy cells mistakenly attack myelin in the central nervous system (brain, optic nerves, and spinal cord). Myelin is a substance...
-
Product Insights
Cognitive Impairment Associated With Schizophrenia (CIAS) - Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment Associated With Schizophrenia (CIAS) – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive functioning is moderately to severely impaired in patients with schizophrenia. Symptoms of cognitive impariment associated with schizophrenia (CIAS) include poor executive functioning, inability to sustain attention, and problems with working memory. Predisposing factors include family history, age, and autoimmune diseases. Treatment includes antipsychotic medications. The Cognitive Impairment Associated With Schizophrenia (CIAS) drugs in development market research report...
-
Product Insights
Multifocal Motor Neuropathy - Drugs In Development, 2024
Empower your strategies with our Multifocal Motor Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Multifocal motor neuropathy (MMN), or multifocal motor neuropathy with conduction block (MMNCB), is a rare acquired motor neuropathy characterized by progressive asymmetric weakness without sensory problems. Symptoms include weakness in the hands and lower arms, cramping, involuntary contractions or twitching, wrist drop, or foot drop. Nerve conduction studies can be used for diagnosis. The main pharmacological treatment option for MMN is...
-
Product Insights
Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) - Drugs In Development, 2024
Empower your strategies with our Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) – Drugs In Development, 2024 report and make more profitable business decisions. Corticobasal degeneration (CBD) or corticobasal syndrome (CBS) is a rare neurological disorder that causes brain cells to die or become damaged. CBD is a form of frontotemporal degeneration, a dementia that involves the loss of cognitive functions that can gradually lead to worsening of movement, speech, memory, and swallowing. Symptoms include a clumsy or useless hand, muscle stiffness,...
-
Product Insights
Lafora Disease (Unverricht Disease) - Drugs In Development, 2024
Empower your strategies with our Lafora Disease (Unverricht Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Unverricht-Lundborg disease (EPM1) a rare and fatal genetic neurodegenerative disorder that causes progressive myoclonic epilepsy. It is caused by mutations of the cystatin B gene. It typically presents in adolescents with new onset seizures along with symptoms such as lack of motor coordination, impaired mental function, and depression. It is diagnosed with a skin biopsy that shows Lafora bodies in...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.